Qin Hao, Wan Yuxiang, Dong Yuchao, Sun Qinying
Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People's Republic of China.
Department of Laboratory Diagnosis, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People's Republic of China.
Cancer Manag Res. 2023 Jul 26;15:765-769. doi: 10.2147/CMAR.S414077. eCollection 2023.
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC), accounting for about 1% of cases. These tumors are characterized by their high malignancy and frequent resistance to chemotherapy, resulting in a worse prognosis compared to other NSCLC subtypes. Currently, there is no established therapeutic strategy for PSC. Recent advancements in targeted therapies have led to the development of ret proto-oncogene (RET) inhibitors, such as selpercatinib and pralsetinib, which have been approved for the treatment of fusion-positive NSCLC patients. Despite their effectiveness in fusion-positive NSCLC is observed, the efficacy of these inhibitors in PSC remains unclear. In this context, we present a case of metastatic PSC harboring de novo fusion. The patient responded to first-line trametinib treatment. These findings suggest that RET inhibitors could be a potential treatment option for metastatic PSC patients with fusion-positive tumors.
肺肉瘤样癌（PSC）是一种罕见的非小细胞肺癌（NSCLC）亚型，约占病例的1%。这些肿瘤具有高恶性和对化疗频繁耐药的特点，与其他NSCLC亚型相比预后更差。目前，尚无针对PSC的既定治疗策略。靶向治疗的最新进展导致了RET原癌基因（RET）抑制剂的开发，如塞尔帕替尼和普拉替尼，它们已被批准用于治疗融合阳性NSCLC患者。尽管观察到它们在融合阳性NSCLC中有效，但这些抑制剂在PSC中的疗效仍不清楚。在此背景下，我们报告了一例携带新发融合的转移性PSC病例。该患者对一线曲美替尼治疗有反应。这些发现表明，RET抑制剂可能是融合阳性肿瘤的转移性PSC患者的一种潜在治疗选择。
